← Back to Screener
Catheter Precision, Inc. (VTAK)
Price$0.97
Favorite Metrics
Price vs S&P 500 (26W)-76.86%
Price vs S&P 500 (4W)-37.94%
Market Capitalization$2.37M
All Metrics
Book Value / Share (Quarterly)$4.06
P/TBV (Annual)0.28x
Revenue Growth (3Y)288.20%
Cash Flow / Share (Quarterly)$-4.85
Price vs S&P 500 (YTD)-56.05%
Gross Margin (TTM)92.31%
Net Profit Margin (TTM)-2098.05%
EPS (TTM)$-19.20
10-Day Avg Trading Volume0.31M
EPS Excl Extra (TTM)$-19.20
Revenue Growth (5Y)25.89%
EPS (Annual)$-15.90
ROI (Annual)-160.02%
Gross Margin (Annual)92.31%
Net Profit Margin (5Y Avg)-65574.92%
Cash / Share (Quarterly)$0.05
Revenue Growth QoQ (YoY)59.73%
ROA (Last FY)-108.34%
Revenue Growth TTM (YoY)95.00%
EBITD / Share (TTM)$-15.38
ROE (5Y Avg)-238.31%
Operating Margin (TTM)-2979.61%
Cash Flow / Share (Annual)$-4.85
P/B Ratio0.34x
P/B Ratio (Quarterly)0.43x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)7.28x
Net Interest Coverage (TTM)-23.05x
ROA (TTM)-74.96%
EPS Incl Extra (Annual)$-15.90
Current Ratio (Annual)0.10x
Quick Ratio (Quarterly)0.06x
3-Month Avg Trading Volume0.80M
52-Week Price Return-86.18%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.06
P/S Ratio (Annual)2.89x
Asset Turnover (Annual)0.05x
52-Week High$15.68
Operating Margin (5Y Avg)-67948.18%
EPS Excl Extra (Annual)$-15.90
CapEx CAGR (5Y)-13.08%
26-Week Price Return-68.11%
Quick Ratio (Annual)0.06x
13-Week Price Return-56.43%
Total Debt / Equity (Annual)0.52x
Current Ratio (Quarterly)0.10x
Enterprise Value$5.964
Revenue / Share Growth (5Y)-36.98%
Asset Turnover (TTM)0.04x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.06x
Pretax Margin (Annual)-2381.56%
Cash / Share (Annual)$0.05
3-Month Return Std Dev141.66%
Gross Margin (5Y Avg)-1553.08%
Net Income / Employee (TTM)$-1
ROE (Last FY)-243.53%
Net Interest Coverage (Annual)-20.02x
EPS Basic Excl Extra (Annual)$-15.90
Receivables Turnover (TTM)7.28x
Total Debt / Equity (Quarterly)0.52x
EPS Incl Extra (TTM)$-19.20
Receivables Turnover (Annual)7.28x
ROI (TTM)-192.76%
P/S Ratio (TTM)2.89x
Pretax Margin (5Y Avg)-67465.94%
Revenue / Share (Annual)$0.76
Tangible BV / Share (Annual)$4.29
Price vs S&P 500 (52W)-121.28%
Year-to-Date Return-51.91%
5-Day Price Return-27.86%
EPS Normalized (Annual)$-15.90
ROA (5Y Avg)-135.32%
Net Profit Margin (Annual)-2098.05%
Month-to-Date Return-12.86%
Cash Flow / Share (TTM)$-52.23
EBITD / Share (Annual)$-15.45
Operating Margin (Annual)-2979.61%
LT Debt / Equity (Annual)0.44x
ROI (5Y Avg)-217.50%
LT Debt / Equity (Quarterly)0.44x
EPS Basic Excl Extra (TTM)$-19.20
P/TBV (Quarterly)8.67x
P/B Ratio (Annual)0.43x
Inventory Turnover (TTM)1.06x
Pretax Margin (TTM)-2381.56%
Book Value / Share (Annual)$4.06
Price vs S&P 500 (13W)-59.30%
Beta-1.19x
Revenue / Share (TTM)$0.48
ROE (TTM)-240.79%
52-Week Low$0.79
Analyst Recommendations
Jun 2025
Jul 2025
Aug 2025
Oct 2025
4.29
4.29
4.29
4.29
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
VTAKCatheter Precision, Inc. | 2.89x | 25.89% | 92.31% | -2979.61% | $0.97 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Cathay Precision Inc is a medical device company specializing in cardiac electrophysiology solutions. Its lead product, the VIVO System, is a non-invasive 3D cardiac mapping platform for identifying ventricular arrhythmia origins prior to EP procedures and holds CE Mark approval for European commercialization. The company is expanding its product portfolio with LockeT, a surgical suture retention device designed to improve wound healing outcomes.